Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

Abstract Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical outcomes in patients treated with both...

Full description

Bibliographic Details
Main Authors: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J. L. Heerspink, Stephanie Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Cardiovascular Diabetology
Subjects:
SGLT2 inhibitor
GLP-1 receptor agonist
Exenatide
Cardiovascular outcomes
eGFR slope
Type 2 diabetes mellitus
Online Access:http://link.springer.com/article/10.1186/s12933-019-0942-x

Internet

http://link.springer.com/article/10.1186/s12933-019-0942-x

Similar Items